Wereldwijde levering met DHL in 7–21 dagen10 flacons per verpakkingVanaf $499: verzending + water gratisBetalen met Coinbase of kaartAffiliates: tot 12% →Alleen voor onderzoekMijn account
BP BioLabsKlinische catalogusShop
Black Week−10% op allesautomatisch verrekend bij het afrekenentot 27 novemberNaar de shop →

Onderzoeksgids

Tirzepatide: what the research shows

Tirzepatide activates two gut-hormone receptors, GIP and GLP-1. How it was tested in the SURPASS and SURMOUNT trials, what the trials found about safety, its regulatory status and how research material differs from the approved medicine.

Bijgewerkt op 23 oktober 2026 · 3 min lezen

Verkrijgbaar in de winkel

Tirzepatidevanaf $173.20 $155.88 / 10 flacons
Tirzepatide flacon

What tirzepatide is

Tirzepatide, development code LY3298176, is a synthetic peptide that activates two receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. It was developed by Eli Lilly and Company. [1] [2] [4]

GIP and GLP-1 are hormones released by the intestine. The FDA describes tirzepatide as activating the receptors of these two hormones to reduce appetite and food intake. [5]

How it has been studied

Tirzepatide was tested in two large phase 3 programmes: SURPASS in type 2 diabetes and SURMOUNT in obesity. The trials below were funded by Eli Lilly. [1] [2] [3]

SURPASS-2 compared tirzepatide head to head with semaglutide, a GLP-1 receptor agonist, in people with type 2 diabetes: at all three doses tested, tirzepatide was non-inferior and superior to semaglutide for the change in HbA1c, and body-weight reductions were also larger. [1]

TrialWho took partLengthMain published result
SURPASS-2 (2021)1,879 adults with type 2 diabetes40 weeksHbA1c down by 2.01 to 2.30 percentage points across doses, against 1.86 with semaglutide [1]
SURMOUNT-1 (2022)2,539 adults with obesity, or overweight with a weight-related condition, without diabetes72 weeksMean body-weight change of -15.0% to -20.9% across the three doses, against -3.1% with placebo [2] [4]
SURMOUNT-1, 3-year analysis (2025)1,032 participants with obesity and prediabetes176 weeks, then 17 weeks off treatmentType 2 diabetes diagnosed in 1.3% against 13.3% with placebo; body-weight change of -12.3% to -19.7% against -1.3% [3]

Verkrijgbaar in de winkel

Tirzepatidevanaf $173.20 $155.88 / 10 flacons

Safety findings reported so far

The most common adverse events were gastrointestinal, mostly mild to moderate and occurring mainly while the dose was being increased. In SURMOUNT-1, adverse events led to stopping treatment in 4.3% to 7.1% of participants on tirzepatide and 2.6% on placebo. [2]

In SURPASS-2, serious adverse events were reported in 5% to 7% of participants on tirzepatide and 3% on semaglutide; nausea, diarrhoea and vomiting were the most frequent complaints in both groups. The three-year SURMOUNT-1 analysis found no new safety signals. [1] [3]

According to the FDA, tirzepatide causes thyroid C-cell tumours in rats, and it is unknown whether it causes such tumours, including medullary thyroid cancer, in humans. [5]

Regulatory status

Tirzepatide is the active ingredient of prescription medicines approved in the United States: first for blood-sugar control in adults with type 2 diabetes and, since 8 November 2023, for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. [5]

An approved medicine is a finished product made and tested for patients and dispensed on prescription. The FDA has warned companies that sold semaglutide, tirzepatide or retatrutide directly to consumers for human use, with dosing instructions, while labelling the products ‘for research purposes’ or ‘not for human consumption’. Research material is not a medicine: it has not been reviewed for safety, effectiveness or quality in people and must not be used in people. We sell tirzepatide only for in vitro laboratory research, without instructions for use. [6]

Storage and stability in the lab

Peptides can degrade through chemical routes such as oxidation, deamidation and hydrolysis and through physical routes such as aggregation, and they are generally more stable in the dry state than in solution. [7]

Lyophilised vials are therefore normally kept cold, dry and away from light until they are reconstituted. The storage statement on the product page and on the batch certificate takes precedence.

How to check a batch

A useful certificate of analysis names the testing laboratory, the batch number printed on the vial, the test date and the methods used. Identity is usually confirmed by mass spectrometry, where the measured mass should match the expected molecular mass, and purity is measured by HPLC.

Where the manufacturer supplies a batch report, we link it on the product page; products without one do not claim one.

Veelgestelde vragen

Is tirzepatide approved?

Yes, as the active ingredient of prescription medicines approved in the United States for type 2 diabetes and, since November 2023, for chronic weight management. Research material sold for laboratory work is not one of those medicines and must not be used in people.

How does tirzepatide compare with semaglutide in trials?

In SURPASS-2, a 40-week trial in 1,879 adults with type 2 diabetes, tirzepatide lowered HbA1c and body weight more than semaglutide at all three doses tested.

What do GIP and GLP-1 stand for?

Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: two hormones released by the intestine. Tirzepatide activates the receptors of both.

Can I buy tirzepatide for personal use?

No. Everything we sell is for in vitro laboratory research by adults aged 21 or over. It is not for use in people or animals, and we give no advice on use or dosing.

Deze gids vat gepubliceerd onderzoek en informatie van toezichthouders samen. Het is geen medisch advies. Alles wat we verkopen is alleen voor in-vitro-laboratoriumonderzoek, door volwassenen van 21+, en niet voor gebruik bij mensen of dieren.